17,421 Shares in Cellebrite DI Ltd. (NASDAQ:CLBT) Acquired by Centiva Capital LP

Centiva Capital LP purchased a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 17,421 shares of the company's stock, valued at approximately $384,000.

Other institutional investors have also recently bought and sold shares of the company. NewEdge Advisors LLC raised its position in Cellebrite DI by 600.7% in the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after purchasing an additional 3,352 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Cellebrite DI in the 4th quarter valued at $100,000. Polen Capital Management LLC bought a new stake in shares of Cellebrite DI during the fourth quarter worth $222,000. Victory Capital Management Inc. acquired a new position in shares of Cellebrite DI during the fourth quarter valued at $234,000. Finally, HighTower Advisors LLC bought a new position in Cellebrite DI in the fourth quarter valued at about $274,000. Institutional investors own 45.88% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CLBT. JPMorgan Chase & Co. dropped their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a report on Monday. Needham & Company LLC lowered their target price on shares of Cellebrite DI from $28.00 to $24.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Lake Street Capital lifted their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI currently has a consensus rating of "Buy" and an average price target of $22.43.

Cellebrite DI Price Performance

CLBT traded down $0.54 during mid-day trading on Thursday, hitting $17.27. The stock had a trading volume of 1,771,749 shares, compared to its average volume of 1,451,941. The stock's fifty day simple moving average is $19.01 and its 200-day simple moving average is $20.25. The firm has a market capitalization of $4.14 billion, a price-to-earnings ratio of -12.42, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 1-year low of $10.25 and a 1-year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, research analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.